Chronic Sildenafil for Severe Diaphragmatic Hernia
| Status: | Completed |
|---|---|
| Conditions: | High Blood Pressure (Hypertension), Gastrointestinal |
| Therapuetic Areas: | Cardiology / Vascular Diseases, Gastroenterology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 5/5/2014 |
| Start Date: | February 2006 |
| End Date: | July 2013 |
| Contact: | Roberta L Keller, MD |
| Email: | kellerr@peds.ucsf.edu |
| Phone: | 415-514-3192 |
The purpose of this study is to test if sildenafil is effective in the treatment of infants
with severe congenital diaphragmatic hernia (determined by the presence of prolonged
pulmonary hypertension or prolonged oxygen supplementation on mechanical ventilation), as
measured by the estimated pulmonary artery systolic pressure following treatment.
with severe congenital diaphragmatic hernia (determined by the presence of prolonged
pulmonary hypertension or prolonged oxygen supplementation on mechanical ventilation), as
measured by the estimated pulmonary artery systolic pressure following treatment.
Congenital diaphragmatic hernia (CDH) is a condition characterized by pulmonary parenchymal
and vascular hypoplasia. Severe CDH carries a high rate of mortality, and significant
morbidity among survivors. This proposal is a randomized, blinded, placebo-controlled study
designed to evaluate the efficacy and potential mechanisms of activity of sildenafil, a
phosphodiesterase-5 inhibitor, for treatment of severe CDH. Infants who meet criteria at
≥10d of age predicting a poor outcome [death or chronic lung disease (CLD) severe enough to
require hospital discharge on supplemental oxygen (O2)] will be eligible for the study.
Infants whose parents consent for the study will undergo an initial echocardiogram to assess
the degree of pulmonary hypertension. They will then begin either sildenafil or placebo
therapy for a 45d course. A final echocardiogram will be performed after the experimental
drug course is completed. The pulmonary arterial systolic pressure estimate during hyperoxic
conditions will be compared between the sildenafil and placebo groups. Infants from either
group who have severely elevated pulmonary arterial pressure (despite supplemental O2) will
be considered for open-label sildenafil, which will continue after hospital discharge,
depending on the results of a cardiac catheterization performed for clinical care.
and vascular hypoplasia. Severe CDH carries a high rate of mortality, and significant
morbidity among survivors. This proposal is a randomized, blinded, placebo-controlled study
designed to evaluate the efficacy and potential mechanisms of activity of sildenafil, a
phosphodiesterase-5 inhibitor, for treatment of severe CDH. Infants who meet criteria at
≥10d of age predicting a poor outcome [death or chronic lung disease (CLD) severe enough to
require hospital discharge on supplemental oxygen (O2)] will be eligible for the study.
Infants whose parents consent for the study will undergo an initial echocardiogram to assess
the degree of pulmonary hypertension. They will then begin either sildenafil or placebo
therapy for a 45d course. A final echocardiogram will be performed after the experimental
drug course is completed. The pulmonary arterial systolic pressure estimate during hyperoxic
conditions will be compared between the sildenafil and placebo groups. Infants from either
group who have severely elevated pulmonary arterial pressure (despite supplemental O2) will
be considered for open-label sildenafil, which will continue after hospital discharge,
depending on the results of a cardiac catheterization performed for clinical care.
Inclusion Criteria:
- Congenital diaphragmatic hernia
- 10-42 days (d) of age
- Significant illness severity as demonstrated by:
- Receiving assisted ventilation and
- FiO2 >= 0.40 at 10-14d of age, or
- FiO2 >= 0.40 for >=48hours at 15-27d of age, or
- FiO2 >= 0.35 at 28-42d of age
- Or, need for extracorporeal support at >=10d of age
- Or, estimated pulmonary arterial or right ventricular systolic pressure of >= 2/3
systemic pressure at 14-42d of age
Exclusion Criteria:
- Structural congenital heart disease (other than patent ductus arteriosus or patent
foramen ovale/atrial septal defect [ASD] or non-hemodynamically significant
ventricular septal defect [VSD])
- Sildenafil contraindicated (until condition resolves):
- Unable to absorb oral medication, or
- Unstable systemic blood pressure, or
- Receiving a drug that may interfere with sildenafil metabolism, or
- Renal insufficiency
- Hepatic insufficiency Previous use of sildenafil
We found this trial at
3
sites
Childrens Hospital Los Angeles Children's Hospital Los Angeles is a 501(c)(3) nonprofit hospital for pediatric...
Click here to add this to my saved trials
225 E Chicago Ave
Chicago, Illinois 60611
Chicago, Illinois 60611
(312) 227-4000
Ann & Robert H. Lurie Children's Hospital of Chicago Ann & Robert H. Lurie Children
Click here to add this to my saved trials
Click here to add this to my saved trials